China's Stairmed raises $210M for brain-computer implants, ranking in the 99th percentile
What's the deal? Stairmed Technology, a Shanghai-based maker of implantable brain-computer interfaces, has raised about US$192.5M in a late-stage round. Investors include Tencent, Alibaba, Geely Capital, CATL, OrbiMed, Qiming Venture Partners, and Lilly Asia VenturesDealroom has a profile for this one. Try Dealroom →. The company says it has raised about US$357.5M to date as of September.
What's the endgame? Founded in August 2021, Stairmed develops minimally invasive implants that decode neural signals into commands for external devices. Its core product, the WRS 01, is a 256-channel system aimed at restoring movement for people with high-level paralysis.
Why now? The WRS 01 completed enrolment for its multi-centre registration trial in August, moving the product into systematic validation. As of October 28, Stairmed reported 42 long-term implants — more, it says, than Neuralink's 27 — with subjects logging over 10,000 hours of brain control.
By the numbers: The round sits in the 99th percentile for late-stage venture deals in China's health sector over the past four years, based on a sample of 238 rounds. The raise lands amid a funding surge: Chinese brain-computer interface startups drew an estimated US$962.5M in the first half of 2026 alone.
Rivals are moving fast too. On the same day, NeuroXess disclosed a US$96.3M raise, with its fully implanted system already in multi-centre registration trials.
What could go wrong? The capital reflects investor bets on clinical translation, not a finished business. Stairmed still must prove long-term safety, clinical benefit, and the ability to manufacture and deliver at scale — and the WRS 01 has not yet been approved for commercial use.
The signal: China now has approved brain-computer interface products on the market, though they use different implant approaches. Stairmed's outsized round shows capital consolidating behind the firms furthest along in clinical trials, as the sector races from experiment toward sustainable medical products.
Read more: sohu.com
Image credit: jurvetson
